Advertisement
RCUS vs SLN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Hold and SLN is a Hold.
RCUS sees MACD Histogram crosses below signal line
RCUS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 42 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 74 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
RCUS moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RCUS crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.863) is normal, around the industry mean (26.782). P/E Ratio (14.389) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for SLN turns negative, indicating new downward trend
SLN saw its Momentum Indicator move below the 0 level on September 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 80 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
SLN moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SLN crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SLN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLN advanced for three days, in 238 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
SLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. SLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.083) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS | SLN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 46 | 45 | |
P/E GROWTH RATING 1..100 | 98 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCUS's Valuation (71) in the Pharmaceuticals Major industry is in the same range as SLN (77) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.
RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SLN (100) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.
RCUS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as SLN (98) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.
SLN's Price Growth Rating (45) in the null industry is in the same range as RCUS (46) in the Pharmaceuticals Major industry. This means that SLN’s stock grew similarly to RCUS’s over the last 12 months.
RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as SLN (100) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.
| RCUS | SLN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 85% | 3 days ago 87% |
| Momentum ODDS (%) | 1 day ago 80% | 6 days ago 90% |
| MACD ODDS (%) | 1 day ago 89% | N/A |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 89% |
| Advances ODDS (%) | 15 days ago 78% | 23 days ago 90% |
| Declines ODDS (%) | 1 day ago 78% | 1 day ago 88% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RCUS’s FA Score shows that 0 FA rating(s) are green while SLN’s FA Score has 0 green FA rating(s).
- RCUS’s FA Score: 0 green, 5 red.
- SLN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RCUS’s TA Score shows that 4 TA indicator(s) are bullish while SLN’s TA Score has 4 bullish TA indicator(s).
- RCUS’s TA Score: 4 bullish, 6 bearish.
- SLN’s TA Score: 4 bullish, 5 bearish.
Price Growth
RCUS (@Biotechnology) experienced а -7.29% price change this week, while SLN (@Biotechnology) price change was -9.77% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.04%. For the same industry, the average monthly price growth was -18.63%, and the average quarterly price growth was -19.43%.
Reported Earning Dates
RCUS is expected to report earnings on Nov 10, 2026.
SLN is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Biotechnology (-8.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBDX | 24.10 | 0.02 | +0.08% |
| iShares iBonds Dec 2032 Term Corporate ETF (IBDX) | |||
| DJUN | 50.66 | N/A | +0.01% |
| FT Vest U.S. Equity Deep Buffer ETF - June (DJUN) | |||
| LFAO | 153.72 | N/A | N/A |
| LifeX 2055 Longevity Income ETF (LFAO) | |||
| ZMAR | 28.74 | N/A | N/A |
| Innovator 1 Yr March (ZMAR) | |||
| OCTM | 34.29 | N/A | -0.01% |
| FT Vest U.S. Equity Max Buffer ETF - October (OCTM) | |||
SLN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLN has been loosely correlated with CLLS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLN jumps, then CLLS could also see price increases.
| Ticker / NAME | Correlation To SLN | 1D Price Change % | ||
|---|---|---|---|---|
| SLN | 100% | -8.08% | ||
| CLLS - SLN | 43% Loosely correlated | -6.78% | ||
| TSHA - SLN | 38% Loosely correlated | -13.53% | ||
| ABCL - SLN | 37% Loosely correlated | -0.20% | ||
| RCUS - SLN | 37% Loosely correlated | -7.52% | ||
| VIR - SLN | 36% Loosely correlated | -6.11% | ||
More | ||||